Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ISRCTN13633989) titled 'A Phase I/IIa trial of NVG-222 in participants with solid tumours' on April 24.
Study Type: Interventional
Study Design:
Multi-centre non-randomized Phase I/IIa open-label dose escalation and dose expansion adaptive design trial (Efficacy, Safety)
Primary Sponsor: Cancer Research UK
Condition:
Solid tumours
Cancer
Intervention:
The dose escalation phase (Phase I) will consist of two parts. In Part I, NVG-222 will be administered in single participant cohorts. These participants will follow accelerated dose escalation, with intra-participant dose escalation permitted. In Part II, NVG-222 will be administered i...